Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

Date

18 March 2019

Pharma's Damaged Reputation

Meagan Parrish writes for Pharma Manufacturing, exploring pharma’s current reputation among the general public. Highlighting some of the recent criticism directed at pharma companies, Meagan also looks at the impact a positive reputation can have.

Direct links

Read the full article

“Pharma companies who are at the top of their reputational game have shown time and again that good governance can be a key driver of profitability and success. Analysts at RI, which measures reputation across numerous industries, have continued to find a strong link between reputation and a company’s bottom line.”

Meagan speaks to Damiano de Felice, Director of Strategy about the research programmes at the Access to Medicine Foundation and how pharma companies can use the indexes to improve their reputation. 

“The general perception is that pharma creates just a win for the companies and not society. We see that many investors and stakeholders now frame the conversation around the ‘license to operate’ … and the importance of pharma maintaining that societal contract so that their business is a win-win for both.”

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved